Torrent Pharma.
Torrent Pharma. Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).
From Torrent Pharma.'s Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023.
- India base business (excluding JB) grew 15% in Q4 FY26, expected to deliver mid-teens growth in FY27, barring external demand shocks.
- Curatio business grew 27% in FY26, with strong outlook for continued traction driven by OTC advertising and field force expansion.
- Brazil market projected to grow 10-15% CAGR over FY26-27 driven by new launches and price increases.
- US business grew 31% INR growth in FY26, with expected single-digit growth on the back of single-digit product launches in FY27.
- JB Pharma salesforce attrition improved; integration expected to enhance revenue synergies over next 2-3 years.
2 more points from Torrent Pharma.'s call on revenue
Every concall, every company
Profitability & Margins
See what Torrent Pharma. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).
- There is interest in in-licensing products, especially from China and other markets, to expand opportunities in India (Page 6).
- For the Semaglutide injectable business in India, potential future manufacturing in-house is considered if the product scales significantly (Page 14).
2 more points from Torrent Pharma.'s call on capex
Every concall, every company
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Torrent Pharma. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Torrent Pharma.'s call on order book
Every concall, every company
Torrent Pharma. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.2K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Torrent Pharmaceuticals Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Arthneeti Pro · Annual
Torrent Pharma. and 1,500+ more calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Torrent Pharma. Q4 FY26 results?
Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).
What is Torrent Pharma. share price analysis?
Torrent Pharma. currently shows a neutral. The stock trades at a P/E of 83.5 with a market cap of ₹186,247 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharma. planning capital expenditure?
Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).
Keep Torrent Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.